ReviewNature reviews. Rheumatology2012
Clinical features of polymyalgia rheumatica and giant cell arteritis.
Review in Nature reviews. Rheumatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05681676 (Is the Melanocortin System Involved in Inflammatory Resolution), which is not on this map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Is the Melanocortin System Involved in Inflammatory Resolution
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 237 citations in OpenAlex.
- Atypical Signs and Symptoms of Giant Cell Arteritis: A Systematic Review.Journal of general internal medicine · 2025Pooled it
- Establishing C-X-C motif chemokine receptor 4 as a novel imaging target in giant cell arteritis.Arthritis research & therapy · 2026Trial
- Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.Arthritis & rheumatology (Hoboken, N.J.) · 2019Trial
- Impact of diabetes mellitus on mortality in patients with giant cell arteritis.EULAR rheumatology open · 2026Article
- Treatment strategies in giant cell arteritis and polymyalgia rheumatica: beyond glucocorticoids.Nature reviews. Rheumatology · 2026Review
- Spatially controlled tenascin-C accumulation contributes to inflammatory disease persistence in giant cell aortitis.JCI insight · 2026Article
- Cytotoxic CD4Signal transduction and targeted therapy · 2026Review
- Characteristics of patients with major relapse in giant cell arteritis: a multicenter case-control study.Clinical rheumatology · 2026Article
- Article
- A prospective cohort study evaluating the role of quantifying sonographic inflammatory changes in GCA.Rheumatology advances in practice · 2025Article
- Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey.Human vaccines & immunotherapeutics · 2024Article
- Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsies.RMD open · 2024Article
- Glucocorticoid discontinuation rate and risk factors for relapses in a contemporary cohort of patients with giant cell arteritis.Rheumatology international · 2024Article
- Giant Cell Arteritis: Advances in Understanding Pathogenesis and Implications for Clinical Practice.Cells · 2024Review
- Characterising polymyalgia rheumatica on whole-bodyRheumatology advances in practice · 2024Review
- Polymyalgia rheumatica: An update (Review).Experimental and therapeutic medicine · 2023Article
- 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Findings of Polymyalgia Rheumatica in Patients with Giant Cell Arteritis.Journal of clinical medicine · 2023Article
- Article
- Water vapor therapy and polymyalgia rheumatica: Coincidental?Journal of family medicine and primary care · 2023Article
- Tongue necrosis secondary to giant cell arteritis.BMJ case reports · 2023Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are inflammatory diseases that typically affect white individuals >50 years. Women are affected ∼2-3 times more often than men. PMR and GCA occur together more frequently than expected by chance. The main symptoms of PMR are pain and stiffness in the shoulders, and often in the neck and pelvic girdle. Imaging studies reveal inflammation of joints and bursae of the affected areas. GCA is a large-vessel and medium-vessel arteritis predominantly involving the branches of the aortic arch. The typical clinical manifestations of GCA are new headache, jaw claudication and visual loss. PMR and GCA usually remit within 6 months to 2 years from disease onset. Some patients, however, have a relapsing course and might require long-standing treatment. Diagnosis of PMR and GCA is based on clinical features and elevated levels of inflammatory markers. Temporal artery biopsy remains the gold standard to support the diagnosis of GCA; imaging studies are useful to delineate large-vessel involvement in GCA. Glucocorticoids remain the cornerstone of treatment of both PMR and GCA, but patients with GCA require higher doses. Synthetic immunosuppressive drugs also have a role in disease management, whereas the role of biologic agents is currently unclear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.